Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer

Phase 2ZoldonrasibNeutral

AI Analysis

Summary

Revolution Medicines announced Phase 1/2 clinical data for Zoldonrasib combination regimens in patients with RAS G12D metastatic pancreatic cancer. The article provides preliminary results from the trial but lacks specific efficacy or safety details.

Clinical Trial Data

Phase

1/2

Importance:6/10

Sentiment:

0.00

oncologyRAS-addicted cancersPhase 1/2 datapancreatic cancercombination therapy

Related Companies

$RVMD

Read the original article

Published by Drugs.com Clinical Trial Results on July 2, 2026 4:07 AM

Read Original